Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

NCT07728721 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: HSK50042 dose 1
DRUG: HSK50042 dose 2
DRUG: HSK50042 dose 3
DRUG: Placebo

Sponsor

Haisco Pharmaceutical Group Co., Ltd.